LIPID THERAPEUTICS
Lipid Therapeutics GmbH was founded in early 2008 in Heidelberg. The mission is to develop novel therapies for inflammatory diseases of the digestive system. The company's current focus is to develop LT-02, a retard formulation of Phosphatidylcholine, for the treatment of Ulcerative colitis based on the preclinical and clinical work conducted by Prof. Stremmel from the University Hospital Heidelberg.
Managing Director
Gerhard Keilhauer, PhD, is a biologist and
chemist and holds a PhD in neurobiology from the University of
Heidelberg.
During his professional career Dr. Keilhauer has gained broad
experience in big pharma as well as in the biotech industry.
Most recently he was as chief development officer of 4SC AG for
almost 7 years responsible for preclinical and clinical
development. Before, he spent almost 16 years with BASF
Pharma/Knoll AG in leading positions in R&D both in Europe as
well as in the US.
Non-executive Director
Christoph Boehringer graduated from the University of Munich with a degree in Mechanical Engineering after completing his training in banking and finance at the private banking establishment Merck Finck& Co. Upon finishing his studies, he deepened his knowledge in the areas of finance, investment and M&A through working at the banking house JP Morgan. He worked for JP Morgan in New York and London.
Mr. Boehringer is founding Partner of Mediatum, an executive recruitment company specializing in the life science industries and he is one of the founding partners of CD-Venture GmbH, as well as of Binder & Associates GmbH.
Since1997 he is also Member of the Shareholders’ Committee of Boehringer Ingelheim, a body comparable to a board of directors of a business quoted on the stock exchange.
Apart from various seats on the boards of directors and consultation at start-up businesses, Mr. Boehringer is a business angel.